

claims in any way, and have merely been made to conform with U.S. claim formatting requirements.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: March 28, 2002

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

APPENDIX TO THE PRELIMINARY AMENDMENT

1. (Amended) Agent for ameliorating low vasopressin level [~~which comprises, as an active ingredient, a~~] comprising at least one substance [~~capable of inhibiting~~] that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.
2. (Amended) The agent for ameliorating low vasopressin level according to claim 1, wherein the substance is an antagonist against a PTHrP receptor.
3. (Amended) The agent for ameliorating low vasopressin level according to claim 1, wherein the substance is an anti-PTHrP antibody.
4. (Amended) The agent for ameliorating low vasopressin level according to claim 1, wherein the substance is at least one of a fragment of an anti-PTHrP antibody [~~and/or~~] and a modified form of the fragment.
5. (Amended) The agent for ameliorating low vasopressin level according to claim 3 or 4, wherein the antibody is a humanized or chimeric antibody.
6. (Amended) The agent for ameliorating low vasopressin level according to claim 5, wherein the [~~humanized~~] antibody is humanized #23-57-137-1 antibody.
7. (Amended) The agent for ameliorating low vasopressin level according to claim 3 or 4, wherein the antibody is a monoclonal antibody.
8. (Amended) The agent for ameliorating low vasopressin level according to any one of claims 1 to [7] 4, wherein the low vasopressin level results from cancer.

9. (Amended) An agent for ameliorating [a] at least one symptom caused by a decrease in vasopressin level [~~which comprises, as an active ingredient, a~~ comprising at least one substance [~~capable of inhibiting~~] that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

10. (Amended) The agent for ameliorating at least one symptom caused by a decrease in vasopressin level according to claim 9, wherein the decrease in vasopressin level results from cancer.

11. (Amended) The agent for ameliorating at least one symptom caused by a decrease in vasopressin level according to claim 9 or 10, wherein the symptom caused by a decrease in vasopressin level is at least one symptom selected from the group consisting of polyuria, dehydration, mouth dryness and hyperosmolarity.

12. (Amended) An agent for ameliorating hyperosmolarity [~~which comprises, as an active ingredient, a~~ comprising at least one substance [~~capable of inhibiting~~] that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

13. (Amended) The agent for ameliorating hyperosmolarity according to claim 12, wherein the hyperosmolarity is associated with at least one of vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

14. (Amended) An agent for ameliorating dehydration [~~which comprises, as an active ingredient, a~~ comprising at least one substance [~~capable of inhibiting~~] that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

15. (Amended) The agent for ameliorating dehydration according to claim 14, wherein the dehydration is associated with at least one of vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com